Literature DB >> 30683462

Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database.

C Lacroix1, F Kheloufi1, F Montastruc2, Y Bennis3, V Pizzoglio4, J Micallef5.   

Abstract

INTRODUCTION: Among antibiotics, Central Nervous System (CNS) adverse drug reactions (ADRs) are often under-suspected and overlooked. Cephalosporins are an important cause of drug-induced CNS ADRs but the characteristics of such ADR have not been fully explored. We aimed to characterize the profile of cephalosporins serious CNS ADRs.
METHOD: We performed an analysis of serious reports recorded in the French Pharmacovigilance database from 1987 to 2017.
RESULTS: A total of 511 serious ADRs reports was analyzed. Patients had a mean age of 67.1 years and were mainly men (52.5%), with a mean creatinine clearance of 32.9 ml/min. The most involved molecules were cefepime (33.1%), ceftriaxone (29.7%), ceftazidime (19.6%), cefotaxime (9%) and cefazoline (2.9%), mostly administered intravenously (87.3%). A CNS history was observed in 25% of the reports (n = 128). Patients exhibited encephalopathy (30.3%), confusional state (19.4%), convulsion (15.1%), myoclonia (9.4%), status epilepticus (9.2%), coma (6.3%) and hallucination (4.3%). The mean time of onset was 7.7 days and the mean duration was 6 days. Cephalosporin plasma levels were recorded for 153 patients (29.9%) and 107 were above the standards including 62 (57.9%) related to renal impairment. Electroencephalograms were performed in 38.2% (n = 195) of the patients and 81% (n = 158) were abnormal.
CONCLUSION: This study characterizes an off-target CNS ADRs of several cephalosporins. Ceftriaxone represented a large part of our reports after cefepime and it would be relevant to warn healthcare professionals. Investigations (EEG, though plasma levels and renal function) can be precious tools for clinicians to make a prompt diagnosis and improve patients' outcomes.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Adverse effects; Antibiotics; Central nervous system; Cephalosporins; Neurologic; Neurotoxicity; Pharmacovigilance; Psychiatric

Mesh:

Substances:

Year:  2019        PMID: 30683462     DOI: 10.1016/j.jns.2019.01.018

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

2.  Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole.

Authors:  Benjamin Lima; Sandra Bodeau; Marie-Charlotte Quinton; Cyril Leven; Anne-Sophie Lemaire-Hurtel; Youssef Bennis
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  Infectious stress triggers a POLG-related mitochondrial disease.

Authors:  Paula Gaudó; Sonia Emperador; Nuria Garrido-Pérez; Eduardo Ruiz-Pesini; Delia Yubero; Angels García-Cazorla; Rafael Artuch; Julio Montoya; María Pilar Bayona-Bafaluy
Journal:  Neurogenetics       Date:  2019-10-26       Impact factor: 2.660

4.  Signal Detection of Adverse Drug Reactions of Cephalosporins Using Data from a National Pharmacovigilance Database.

Authors:  Jung-Yoon Choi; Jae-Hee Choi; Myeong-Gyu Kim; Sandy-Jeong Rhie
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02

5.  Serious Neurological Adverse Events of Ceftriaxone.

Authors:  Clémence Lacroix; Annie-Pierre Bera-Jonville; François Montastruc; Lionel Velly; Joëlle Micallef; Romain Guilhaumou
Journal:  Antibiotics (Basel)       Date:  2021-05-06

Review 6.  Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice.

Authors:  Shawniqua Williams Roberson; Mayur B Patel; Wojciech Dabrowski; E Wesley Ely; Cezary Pakulski; Katarzyna Kotfis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 7.  Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan.

Authors:  Fumiya Ebihara; Yukihiro Hamada; Hideo Kato; Takumi Maruyama; Toshimi Kimura
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.